<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41798">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562235</url>
  </required_header>
  <id_info>
    <org_study_id>15681</org_study_id>
    <secondary_id>2014-003952-29</secondary_id>
    <nct_id>NCT02562235</nct_id>
  </id_info>
  <brief_title>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>PATENT-CHILD</acronym>
  <official_title>Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0
      mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary
      arterial hypertension (PAH) group 1. The study consists of two phases: titration phase up to
      8 weeks and a maintenance phase up to 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Anticipated">December 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incidence of treatment-emergent adverse events</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in incidence of treatment-emergent serious adverse events</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone age x-ray of left hand</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of riociguat</measure>
    <time_frame>Day 0, Day 1 (0.5, 1.5 and 2.5h), Day 28, Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-Minute Walking Distance (6MWD)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO functional class</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP or BNP (N-terminal pro-brain natriuretic peptide)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiograph from baseline</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life scores as assessed by patient questionnaire and PedsQL generic score</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Parent questionnaire and in children able to understand questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire to assess both taste and texture of pediatric formulation(s)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Body-weight adjusted dose equivalent to the exposure of (0.5mg) 1.0 - 2.5 mg three times a day (TID), individual dose titration (IDT) in adults treated for PAH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>The individual optimal (maintenance) dose is to be determined based on patients' monitoring of systolic blood pressure, well-being and clinical status.</description>
    <arm_group_label>Riociguat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged ≥6 to &lt;18 years

          -  Diagnosed with PAH :

               -  Idiopathic (IPAH)

               -  Hereditable (HPAH)

               -  PAH associated with (APAH)

               -  Connective tissue disease

               -  Congenital heart disease with shunt closure more than 6 months ago (no open
                  shunts, confirmed by RHC no less than 4 months after surgery)

          -  Diagnosis of PAH confirmed by right heart catheterization (RHC) at any time prior to
             enrolment (for patients with closed shunts - RHC no less than 4 months after surgery)

          -  Pulmonary arterial hypertension confirmed by a RHC at any time prior to start of
             study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest, pulmonary
             capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP)
             ≤15 mmHg, and pulmonary vascular resistance (PVR) &gt;240 dyn•sec•cm-5 (i.e., ≥3.0 wood
             units•m2)

          -  Patients must be on standard of care PAH medications, allowing Endothelin Receptor
             Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to
             baseline visit.

          -  Two groups of patients will be included:

               -  Prevalent: Patients currently on monotherapy who need additional treatment
                  (discretion of the investigator)

               -  Incident: Treatment naïve patients initiated on PAH medication (allowing ERA and
                  /or PCA) and then riociguat added once patinets are stable on standard of care

          -  WHO functional class I-III

          -  Adolescent females of childbearing potential can only be included in the study if a
             pregnancy test is negative. Adolescent females of childbearing potential must agree
             to use adequate contraception when sexually active. 'Adequate contraception' is
             defined as any combination of at least 2 effective methods of birth control, of which
             at least one is a physical barrier (e.g. condoms with hormonal contraception or
             implants or combined oral contraceptives, certain intrauterine devices). Adequate
             contraception is required from the signing of the informed consent form up until 6
             weeks after the last study drug administration.

          -  Young men must agree to use adequate contraception when sexually active.

          -  Written inform consent provided and if applicable child assent provided

        Exclusion Criteria:

          -  Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors
             (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE)
             inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite)
             in any form

          -  Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1

          -  Active state of hemoptysis or pulmonary hemorrhage, including those events managed by
             bronchial artery embolization or any history of bronchial artery embolization or
             massive hemoptysis within 3 months prior to screening

          -  Systolic blood pressure (SBP) more than 5 mmHg lower than the age-, sex- and
             height-adapted level of the 50th SBP percentile (NHBPEP, 2004)

          -  History of left-sided heart disease, including valvular disease or heart failure

          -  Pulmonary hypertension related to conditions other than specified in the inclusion
             criteria

          -  Pulmonary veno-occlusive disease

          -  Screening aspartate transaminase (AST) and/ or alanine transaminase (ALT) more than 3
             times the upper limit of normal (ULN)

          -  Severe restrictive lung disease

          -  Severe congenital abnormalities of the lung, thorax, and diaphragm

          -  Clinically relevant hepatic dysfunction (especially Child Pugh C)

          -  Renal insufficiency (estimated glomerular filtration rate &lt;30 mL/min/1.73m2 e.g.
             calculated based on Schwartz formula, for detailed calculation instructions

          -  PH associated with idiopathic interstitial pneumonia (PH-IIP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <state>Valle del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy National Cardiology Institute</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico D.F.</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <zip>400001</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>September 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
